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Ellis-van Creveld syndrome (EVC, MIM ID 225500), a rare ciliopathy, is an autosomal 
recessive, congenital disorder occurring in about 1 in 60,000 live births. EVC is characterized 
by disproportionate short stature, polydactyly, dystrophic nails and specific oral defects. More 
than half of EVC cases have severe congenital heart defects, which lead to early childhood 
mortality. Causative mutations of either the EVC or EVC2 gene are detected in two-thirds of 
EVC. WDR35 mutation has also been reported in some cases. The clinical manifestations of 
EVC are overlapping with other ciliopathies, which hampers accurate diagnosis.  Both the EVC 
and EVC2 proteins are localized to the basal bodies of the primary cilia and are considered to 
positively regulate Hh signaling with other molecules. Recently, EFCAB7 and IQCE 
reportedly co-localized with EVC-EVC2 complex and interact with one another. Based on this 
finding, I hypothesized that mutations in EFCAB7 and IQCE may also contribute to EVC 
phenotype. In this study, I conducted clinical and genetic studies of EVC in Vietnam, where no 
data on EVC have been available so far. Seven unrelated Ellis-van Creveld families within 3 
generations were recruited at Children’s Hospital 2, Ho Chi Minh City, Vietnam.  
All the cases shared common EVC manifestations: moderate to severe short stature, oral 
abnormalities, nail dystrophy and CHD. Eight of them had polydactyly/syndactyly of hands 
and feet. Six patients had atrio-ventricular septal defect (AVSD), 2 of them had pulmonary 
stenosis associated with AVSD. Common atrium, the most severe CHD in EVC, were detected 
in two cases. Interestingly, two patients in one EVC family had short chordae, an extremely 
rare CHD, which was never reported in EVC patients.  
I screened EVC-complex genes and WDR35 for the first time in patients with Ellis-van 
Creveld syndrome in Vietnam. Two compound heterozygous mutations (c.769G>T and 
c.2476C>T) in EVC2 were found in patient C2, which was inherited from mother and father, 
respectively. Both of them were truncated mutations, one was inherited from farther and 
another from mother. The parents showed variable phenotypes; her father had mild EVC 
phenotype while the mother had only short stature. One of the possible explanations for the 
difference in severity between the parents is somatic mosaic. However, both the parents showed 
the same mutation in genomic DNA samples from the different tissues. The modulating factors 
determining the disease severity in each mutation remains unknown.  
Compound heterozygous mutations of EVC (c.1715C>G-p.S572X, 16.4kb partial 
deletion-del IVS8-11) and heterozygous EFCAB7 c.1171T>C (p.Y391H) was detected in one 
positive-EVC family. The genotype-phenotype expression in each family member raised a 
question whether EFCAB7 mutation played a role on the pathogenesis of EVC. RNA 
expression of EFCAB7 is recognized in various organs, however, protein expression is only 
detected in fetal heart. It was suggested that EFCAB7 expression is spatiotemporally regulated 
and important for normal cardiac development. So far, EFCAB7 mutations have neither been 
reported as the cause of congenital human diseases, nor as somatic mutations detected in such 
as neoplasmic tissues. A previous study reported that in vitro depletion of EFCAB7 
downregulates expression of EVC2 and IQCE mRNA. However, the role of missense mutation 
in EFCAB7 has not yet been studied. EFCAB7 recruits the EVC-EVC2 complex by interactions 
between mainly ECH2, a domain of EFCAB7, and the WEYER peptides of EVC2. In this 
study, a missense mutation located in ECH1 domain, which also binds to WEYER, resulting in 
a stronger binding to WEYER compared to wild-type ECH1. The complex of WEYER and 
EFCAB7 activates Hh signaling. The alteration of binding capacity might affect the Hh 
signaling regulation. Previous studies have observed the binding of EFCAB7 to EVC2, and a 
notable association of expression levels of EVC-EVC2 and EFCAB7-IQCE. In addition, the 
presence of interaction partner (EVC to EVC2 and EFCAB7 to IQCE) induces expression of 
another. Based on these findings, I tested whether mRNA expression of EVC, EVC2 and IQCE 
were altered by transfection of mutated EFCAB7. A possible explanation for the significant 
lower expression of the binding partner IQCE with mutated EFCAB7 than with wild one, was 
that the mutated EFCAB7 may be less stable than wild-type EFCAB7. On the contrary, EVC 
mRNA expression was upregulated more in the presence of mutated EFCAB7 compared with 
wild-type. Recent report revealed that SUFU missense variant transfection increased the basal 
expression levels of the key Sonic Hh signaling - target genes BCL2, GLI1, and PTCH1 
compared to control. It is suggested that missense variant in a gene could modulate other genes 
in the same signal transduction pathway. Transfection of shRNA EVC together with wild-type 
EFCAB7 severely perturbed the expression of EVC2. Whereas EVC2 expression was not 
altered in mutated EFCAB7 cells, the EVC2 mRNA expression level was reassessed (20% of 
normal level) in co-transfection shRNA EVC and EFCAB7 1171C. It suggested that mutated 
EFCAB7 1171C might increase EVC2 mRNA expression in EVC knockdown cells. Taken 
together, both EFCAB7 and EVC may be required for normal EVC2 transcription. Moreover, 
the ratio of GLI3R/GLI3FL in co-transfected cells (shRNA EVC and mutated EFCAB7) was 
significantly different from that in shRNA EVC and wild-type EFCAB7 also imply that mutated 
EFCAB7 modulate Hh signaling together with EVC depletion. 
In conclusion, I found compound heterozygous mutations of EVC and EVC2 genes in 
Vietnamese families diagnosed with EVC. The relative expression of EVC/EVC2 mRNA was 
reduced in these mutation carriers, which revealed that these mutations were disease-causative. 
Moreover, EFCAB7 c.1171T>C (p.Y391H) mutation was firstly co-detected in positive-EVC 
cases, which modified EFCAB7-EVC2 interaction and GLI3 activation in Hh signaling. It 
suggested that EFCAB7 is a genetic modifier of EVC. 
 
